Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer

被引：48

作者：

Go, Se-Il ^{[1
]}

Kim, Rock Bum ^{[2
,3
]}

Song, Haa-Na ^{[1
]}

Kang, Myoung Hee ^{[1
]}

Lee, Un Seok ^{[1
]}

Choi, Hye Jung ^{[1
]}

Lee, Seung Jun ^{[4
]}

Cho, Yu Ji ^{[4
]}

Jeong, Yi Yeong ^{[4
]}

Kim, Ho Cheol ^{[4
]}

Lee, Jong Deog ^{[4
]}

Kim, Seok-Hyun ^{[5
]}

Kang, Jung-Hun ^{[1
,6
]}

Ling, Hui ^{[7
]}

Lee, Gyeong-Won ^{[1
,6
]}

机构：

[1] Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Div Hematol Oncol, Dept Internal Med,Sch Med, Jinju 660702, South Korea

[2] Dong A Univ Coll Med, Dept Prevent Med, Busan 602715, South Korea

[3] Dong A Univ Coll Med, Ctr Environm Hlth, Busan 602715, South Korea

[4] Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Div Resp & Crit Care Med, Dept Internal Med,Sch Med, Jinju 660702, South Korea

[5] Sungkyunkwan Univ, Samsung Changwon Hosp, Dept Internal Med, Div Hematol & Med Oncol,Sch Med, Chang Won 630723, South Korea

[6] Gyeongsang Inst Hlth Sci, Jinju 660702, South Korea

[7] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

来源：

MEDICAL ONCOLOGY | 2014年 / 31卷 / 12期

关键词：

Lymphocyte; Monocyte; Small cell lung carcinoma; Overall survival; TUMOR-INFILTRATING LYMPHOCYTES; SURVIVAL; STAGE; CHEMOTHERAPY; SURVEILLANCE; THERAPY;

D O I：

10.1007/s12032-014-0323-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated the role of the lymphocyte-to-monocyte ratio (LMR) at diagnosis in patients with small cell lung cancer (SCLC) treated with standard chemotherapy. We retrospectively reviewed all SCLC patients who received frontline platinum-based chemotherapy or chemoradiotherapy. The cut-off LMR value at diagnosis was 4.19 according to time-dependent receiver-operating characteristic analysis. A total of 188 patients were divided into two groups according to the LMR at diagnosis (low vs. high LMR). Of the 171 patients evaluated for treatment response, 14 (12.4 %) in the low LMR group and 1 (1.7 %) in the high LMR group were non-responders (p = 0.025). In the whole patient cohort, progression-free survival and overall survival were significantly shorter in the low LMR group (low vs. high: median 6.4 vs. 7.1 months, p = 0.001; median 10.6 vs. 13.1 months, p = 0.003, respectively). On multivariate analysis, a low LMR at diagnosis was an independent unfavourable prognostic factor for predicting survival. The LMR at diagnosis could be helpful for predicting prognosis in SCLC.

引用

页码：1 / 7

页数：7

共 39 条

[1] Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer [J].